KLRS
Kalaris Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.50 EPS
Last earnings +1.3% on 2026-05-12
$4.32
▲ +0.47%$4.32▲ +83.05%
over 1Y
L $2.27EODHDH $10.98
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W-1.8%
1M-17.6%
3M-19.9%
YTD-48.0%
1Y+83.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.54x); but unprofitable (net margin -26326.1%).
Revenue (FY2019) $165K · FY2019
Kalaris Therapeutics, Inc. shows $165K in FY2019 revenue, a -26326.1% net margin, and -55.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$170M | -$171M | -$200M | -$51.7M | -$46.2M |
| Net income | -$172M | -$169M | -$190M | -$69.2M | -$43.4M |
| Diluted EPS | -$2.74 | -$2.20 | -$42.09 | -$51.77 | -$2.85 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$996K
EV / EBITDA—
EV / Sales6.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-43.9%
FCF yield-38.9%
Quality & risk
ROIC (est.)-46.3%
Free cash flow-$38.6M
Total debt—
Net cash$98.1M
Altman Z-Score-0.63 distress
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+354.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Shareholder vote2026-06-04
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- DEF 14A Proxy statement2026-04-24
- 8-K Officer / director change2026-04-10
- S-3 Shelf registration (potential raise)2026-04-03
- S-3 Shelf registration (potential raise)2026-04-03
- 8-K Earnings results2026-03-17
- 10-K Annual report2026-03-17
Recent filings
all on EDGAR ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗8-KPeriod ending 2026-06-032026-06-04open ↗SCHEDULE 13D/AFiling2026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗
Frequently asked
- Is Kalaris Therapeutics, Inc. (KLRS) a buy?
- KLRS currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.54x); but unprofitable (net margin -26326.1%).
- What is Kalaris Therapeutics, Inc.'s quality score?
- KLRS scores 48.56862745098039/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001754068, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:36:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.